Flowcytometry analysis revealed that treatment with HA-CPNs causes significant downregulation of glioma cells positive for both CD44 and CD133 markers (CD44 + , CD133 +) leading to overall decrease of TICs in the studied population with significant increase of cells negative for either of the TIC markers (CD44-, CD133-) (Fig. 5A). The gene discussed is PROM1; the disease is glioma.